Mantle Cell Lymphoma (MCL)
Results from the Belgian mantle cell lymphoma registry
8
Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers
49
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.: MRD after immunochemotherapy in mantle-cell lymphoma
32
Resistance to the proteasome inhibitors: Lessons from multiple myeloma and mantle cell lymphoma
32
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project
20
The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma
9
Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma.
5
The REFRACT-LYMA cohort study: a French observational prospective cohort study of patients with mantle cell lymphoma.
9
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
11
Management of Drug Resistance in Mantle Cell Lymphoma
26
Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed mantle cell lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.
9
en fr Physiopathology of mantle cell lymphoma from mechanistic to preclinical models Physiopathologie du lymphome à cellules du manteau : de la mécanistique aux modèles précliniques
229
BMP7 Expression Correlates with Secondary Drug Resistance in Mantle Cell Lymphoma
10
Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma.
15
Treatment of mantle cell lymphomas: recommendations of the Belgian Hematological Society
8
Farnesyltransferase inhibitor R115777 inhibits cell growth and induces apoptosis in mantle cell lymphoma.
2
Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma
11
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non- Hodgkin lymphoma involves modulation of G2/M cell cycle arrest
15
Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets.: Molecular Signature of Hepatosplenic T-cell Lymphoma
41
Description of Two Cases of Anaplastic Large Cell Lymphoma Associated with a Breast Implant
7